# Firefly Neuroscience, Inc.: financial statements, quarterly

AIFF · Nasdaq · CIK 803578 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/aiff.md) · [Financials](/companies/aiff/financials.md) · [Filings](/companies/aiff/filings.md) · [Insiders](/companies/aiff/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/aiff/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001437749-24-035393.md) | [0.0 d](/filings/0001437749-25-010818.md) | [0.0](/filings/0001437749-25-016587.md) | [0.0](/filings/0001437749-25-026538.md) | [0.0](/filings/0001213900-25-108474.md) | [0.1 d](/filings/0001437749-26-010500.md) | [0.0](/filings/0001437749-26-016501.md) | [0.3](/filings/0001437749-26-026822.md) | [0.4](/filings/0001213900-25-108474.md) | [0.4 d](/filings/0001437749-26-010500.md) | [0.5](/filings/0001437749-26-016501.md) | [0.5](/filings/0001437749-26-026822.md) |
| Cost of revenue | $m | not reported | not reported | not reported | [0.0](/filings/0001437749-25-026538.md) | not reported | not reported | [0.0](/filings/0001437749-26-016501.md) | [0.0](/filings/0001437749-26-026822.md) | [0.2](/filings/0001213900-25-108474.md) | [0.2 d](/filings/0001437749-26-010500.md) | [0.3](/filings/0001437749-26-016501.md) | [0.3](/filings/0001437749-26-026822.md) |
| Gross profit | $m | [0.6](/filings/0001437749-23-031501.md) | [0.6 d](/filings/0001437749-24-008626.md) | [0.7](/filings/0001437749-24-016602.md) | [0.0](/filings/0001437749-25-026538.md) | [0.0](/filings/0001213900-25-108474.md) | [0.1 d](/filings/0001437749-26-010500.md) | [0.0](/filings/0001437749-26-016501.md) | [0.3](/filings/0001437749-26-026822.md) | [0.1](/filings/0001213900-25-108474.md) | [0.2 d](/filings/0001437749-26-010500.md) | [0.2](/filings/0001437749-26-016501.md) | [0.3](/filings/0001437749-26-026822.md) |
| Research and development | $m | [0.4](/filings/0001437749-24-035393.md) | [0.0 d](/filings/0001437749-25-010818.md) | [0.3](/filings/0001437749-25-016587.md) | [0.4](/filings/0001437749-25-026538.md) | [0.9](/filings/0001213900-25-108474.md) | [0.4 d](/filings/0001437749-26-010500.md) | [0.3](/filings/0001437749-26-016501.md) | [0.3](/filings/0001437749-26-026822.md) | [0.4](/filings/0001213900-25-108474.md) | [0.5 d](/filings/0001437749-26-010500.md) | [0.4](/filings/0001437749-26-016501.md) | [0.5](/filings/0001437749-26-026822.md) |
| Selling, general and administrative | $m | [1.2](/filings/0001437749-23-031501.md) | [1.4 d](/filings/0001437749-24-008626.md) | [1.4](/filings/0001437749-24-016602.md) | [1.1](/filings/0001437749-24-027242.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(0.6)](/filings/0001437749-24-035393.md) | [(1.6) d](/filings/0001437749-25-010818.md) | [(1.1)](/filings/0001437749-25-016587.md) | [(1.3)](/filings/0001437749-25-026538.md) | [(4.3)](/filings/0001213900-25-108474.md) | [(3.4) d](/filings/0001437749-26-010500.md) | [(2.1)](/filings/0001437749-26-016501.md) | [(1.6)](/filings/0001437749-26-026822.md) | [(2.7)](/filings/0001213900-25-108474.md) | [(2.5) d](/filings/0001437749-26-010500.md) | [(2.0)](/filings/0001437749-26-016501.md) | [(2.0)](/filings/0001437749-26-026822.md) |
| Interest expense | $m | [0.0](/filings/0001437749-23-031501.md) | [0.0 d](/filings/0001437749-24-008626.md) | [0.0](/filings/0001437749-24-016602.md) | [0.0](/filings/0001437749-24-027242.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.0](/filings/0001437749-24-035393.md) | [0.0 d](/filings/0001437749-25-010818.md) | [0.0](/filings/0001437749-25-016587.md) | [0.0](/filings/0001437749-25-026538.md) | [0.0](/filings/0001437749-24-035393.md) | [(0.0) d](/filings/0001437749-26-010500.md) | [0.0](/filings/0001437749-26-016501.md) | [0.0](/filings/0001437749-26-026822.md) | [0.0 d](/filings/0001213900-25-108474.md) | [0.0 d](/filings/0001437749-26-010500.md) | [0.0](/filings/0001437749-26-016501.md) | [0.0](/filings/0001437749-26-026822.md) |
| Net income | $m | [(0.7)](/filings/0001437749-24-035393.md) | [(1.1) d](/filings/0001437749-25-010818.md) | [(1.1)](/filings/0001213900-25-108474.md) | [(1.3)](/filings/0001213900-25-108474.md) | [(4.3)](/filings/0001213900-25-108474.md) | [(3.8) d](/filings/0001437749-26-010500.md) | [(12.9)](/filings/0001437749-26-026822.md) | [(1.8)](/filings/0001437749-26-026822.md) | [(2.6)](/filings/0001213900-25-108474.md) | [(2.5) d](/filings/0001437749-26-010500.md) | [(2.0)](/filings/0001437749-26-026822.md) | [(2.0)](/filings/0001437749-26-026822.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | [(0.58)](/filings/0001437749-24-027242.md) | [(0.61)](/filings/0001213900-25-108474.md) | not reported | not reported | not reported | [(0.20)](/filings/0001213900-25-108474.md) | not reported | not reported | not reported |
| Basic EPS | $ per share | [(0.18)](/filings/0001437749-24-035393.md) | not reported | [(0.22)](/filings/0001437749-25-016587.md) | [(0.24)](/filings/0001437749-25-026538.md) | [(0.61)](/filings/0001213900-25-108474.md) | not reported | [(1.74)](/filings/0001437749-26-016501.md) | [(0.14)](/filings/0001437749-26-026822.md) | [(0.20)](/filings/0001213900-25-108474.md) | not reported | [(0.13)](/filings/0001437749-26-016501.md) | [(0.10)](/filings/0001437749-26-026822.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.9](/filings/0001437749-23-031501.md) | [0.7](/filings/0001437749-24-027242.md) | [0.6](/filings/0001437749-24-016602.md) | [0.2](/filings/0001437749-24-027242.md) | [1.2](/filings/0001437749-24-035393.md) | [1.8](/filings/0001437749-26-010500.md) | [9.5](/filings/0001437749-25-016587.md) | [5.9](/filings/0001437749-25-026538.md) | [4.3](/filings/0001213900-25-108474.md) | [2.7](/filings/0001437749-26-026822.md) | [3.1](/filings/0001437749-26-016501.md) | [9.2](/filings/0001437749-26-026822.md) |
| Current assets | $m | [2.7](/filings/0001437749-23-031501.md) | [2.3](/filings/0001437749-25-010818.md) | [1.6](/filings/0001437749-24-016602.md) | [1.2](/filings/0001437749-24-027242.md) | [2.7](/filings/0001437749-24-035393.md) | [2.6](/filings/0001437749-26-010500.md) | [10.4](/filings/0001437749-25-016587.md) | [7.5](/filings/0001437749-25-026538.md) | [5.4](/filings/0001213900-25-108474.md) | [4.0](/filings/0001437749-26-026822.md) | [4.5](/filings/0001437749-26-016501.md) | [10.2](/filings/0001437749-26-026822.md) |
| Total assets | $m | [5.3](/filings/0001437749-23-031501.md) | [2.6](/filings/0001437749-25-010818.md) | [3.8](/filings/0001437749-24-016602.md) | [3.3](/filings/0001437749-24-027242.md) | [5.3](/filings/0001437749-24-035393.md) | [4.6](/filings/0001437749-26-010500.md) | [12.4](/filings/0001437749-25-016587.md) | [14.9](/filings/0001437749-25-026538.md) | [12.4](/filings/0001213900-25-108474.md) | [10.5](/filings/0001437749-26-026822.md) | [10.9](/filings/0001437749-26-016501.md) | [16.8](/filings/0001437749-26-026822.md) |
| Current liabilities | $m | [2.2](/filings/0001437749-23-031501.md) | [2.5](/filings/0001437749-25-010818.md) | [2.0](/filings/0001437749-24-016602.md) | [1.9](/filings/0001437749-24-027242.md) | [2.5](/filings/0001437749-24-035393.md) | [5.0](/filings/0001437749-26-010500.md) | [7.2](/filings/0001437749-25-016587.md) | [2.8](/filings/0001437749-25-026538.md) | [2.7](/filings/0001213900-25-108474.md) | [2.8](/filings/0001437749-26-026822.md) | [2.5](/filings/0001437749-26-016501.md) | [2.1](/filings/0001437749-26-026822.md) |
| Total liabilities | $m | [2.4](/filings/0001437749-23-031501.md) | [2.5](/filings/0001437749-25-010818.md) | [2.1](/filings/0001437749-24-016602.md) | [1.9](/filings/0001437749-24-027242.md) | [2.5](/filings/0001437749-24-035393.md) | [5.0](/filings/0001437749-26-010500.md) | [7.2](/filings/0001437749-25-016587.md) | [2.8](/filings/0001437749-25-026538.md) | [2.8](/filings/0001213900-25-108474.md) | [2.8](/filings/0001437749-26-026822.md) | [2.5](/filings/0001437749-26-016501.md) | [2.1](/filings/0001437749-26-026822.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(1.0)](/filings/0001437749-24-035393.md) | [0.1](/filings/0001437749-26-010500.md) | [(0.0)](/filings/0001213900-25-108474.md) | [(1.2)](/filings/0001213900-25-108474.md) | [(2.8)](/filings/0001213900-25-108474.md) | [(0.4)](/filings/0001437749-26-026822.md) | [5.2](/filings/0001437749-26-026822.md) | [12.1](/filings/0001437749-26-026822.md) | [9.7](/filings/0001213900-25-108474.md) | [7.6](/filings/0001437749-26-026822.md) | [8.4](/filings/0001437749-26-026822.md) | [14.7](/filings/0001437749-26-026822.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [492 d](/filings/0001437749-24-035393.md) | [(510) d](/filings/0001437749-25-010818.md) | [(1,319)](/filings/0001437749-25-016587.md) | [(1,099) d](/filings/0001437749-25-026538.md) | [(2,519) d](/filings/0001213900-25-108474.md) | [(1,218) d](/filings/0001437749-26-010500.md) | [(2,511)](/filings/0001437749-26-016501.md) | [(2,390) d](/filings/0001437749-26-026822.md) | [(1,488) d](/filings/0001213900-25-108474.md) | [(1,805) d](/filings/0001437749-26-010500.md) | [(1,948)](/filings/0001437749-26-016501.md) | [(1,750) d](/filings/0001437749-26-026822.md) |
| Capital expenditure | $k | [0.0 d](/filings/0001437749-23-031501.md) | [0.0 d](/filings/0001437749-24-008626.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q2 FY2020 (2020-06-30) | Q3 FY2020 (2020-09-30) | Q1 FY2021 (2021-03-31) | Q2 FY2021 (2021-06-30) | Q3 FY2021 (2021-09-30) | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q2 FY2023 (2023-06-30) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q3 FY2025 (2025-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [11.2](/filings/0001437749-21-020718.md) | [11.8](/filings/0001437749-21-024909.md) | [12.3](/filings/0001437749-22-012638.md) | [12.7](/filings/0001437749-22-020534.md) | [12.6](/filings/0001437749-22-027836.md) | [17.3](/filings/0001437749-22-012638.md) | [17.3](/filings/0001437749-23-023323.md) | [18.4](/filings/0001437749-22-027836.md) | [0.6](/filings/0001437749-24-027242.md) | [0.7](/filings/0001437749-24-027242.md) | [7.1](/filings/0001213900-25-108474.md) | [13.5](/filings/0001213900-25-108474.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 15,690,316 at 2026-08-04, from the cover of the [10-Q filed 2026-08-11](/filings/0001437749-26-026822.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:24 ET. No prices; not investment advice.